These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 38589002)

  • 1. Ablation of IFNγ in myeloid cells suppresses liver inflammation and fibrogenesis in mice with hepatic small heterodimer partner (SHP) deletion.
    Zhu L; Litts B; Wang Y; Rein JA; Atzrodt CL; Chinnarasu S; An J; Thorson AS; Xu Y; Stafford JM
    Mol Metab; 2024 May; 83():101932. PubMed ID: 38589002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
    Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
    J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFNγ-IL12 axis regulates intercellular crosstalk in metabolic dysfunction-associated steatotic liver disease.
    Friedline RH; Noh HL; Suk S; Albusharif M; Dagdeviren S; Saengnipanthkul S; Kim B; Kim AM; Kim LH; Tauer LA; Baez Torres NM; Choi S; Kim BY; Rao SD; Kasina K; Sun C; Toles BJ; Zhou C; Li Z; Benoit VM; Patel PR; Zheng DXT; Inashima K; Beaverson A; Hu X; Tran DA; Muller W; Greiner DL; Mullen AC; Lee KW; Kim JK
    Nat Commun; 2024 Jun; 15(1):5506. PubMed ID: 38951527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective Effects of Hepatocyte Stress Defenders, Nrf1 and Nrf2, against MASLD Progression.
    Akl MG; Li L; Widenmaier SB
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissociation of diabetes and obesity in mice lacking orphan nuclear receptor small heterodimer partner.
    Park YJ; Kim SC; Kim J; Anakk S; Lee JM; Tseng HT; Yechoor V; Park J; Choi JS; Jang HC; Lee KU; Novak CM; Moore DD; Lee YK
    J Lipid Res; 2011 Dec; 52(12):2234-2244. PubMed ID: 21949050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic-specific Pgc-1α ablation drives fibrosis in a MASH model.
    Arconzo M; Piccinin E; Pasculli E; Cariello M; Loiseau N; Bertrand-Michel J; Guillou H; Matrella ML; Villani G; Moschetta A
    Liver Int; 2024 Oct; 44(10):2738-2752. PubMed ID: 39046166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    Zou A; Magee N; Deng F; Lehn S; Zhong C; Zhang Y
    J Biol Chem; 2018 Jun; 293(22):8656-8671. PubMed ID: 29666185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion of hepatic small heterodimer partner ameliorates development of nonalcoholic steatohepatitis in mice.
    Lee YK; Park JE; Lee M; Mifflin R; Xu Y; Novak R; Zhang Y; Hardwick JP
    J Lipid Res; 2023 Nov; 64(11):100454. PubMed ID: 37827334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver.
    Huang J; Iqbal J; Saha PK; Liu J; Chan L; Hussain MM; Moore DD; Wang L
    Hepatology; 2007 Jul; 46(1):147-57. PubMed ID: 17526026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution.
    Yu W; Zhang Y; Sun L; Huang W; Li X; Xia N; Chen X; Wikana LP; Xiao Y; Chen M; Han S; Wang Z; Pu L
    Metabolism; 2024 Jun; 155():155911. PubMed ID: 38609037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of hepatic ChREBP⍺-CYP2C50 axis-driven fatty acid oxidation sensitizes mice to diet-induced MASLD/MASH.
    Zhang D; Zhao Y; Zhang G; Lank D; Cooke S; Wang S; Nuotio-Antar A; Tong X; Yin L
    Mol Metab; 2024 Jul; 85():101957. PubMed ID: 38740087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy.
    Wang Q; Bu Q; Xu Z; Liang Y; Zhou J; Pan Y; Zhou H; Lu L
    Clin Mol Hepatol; 2024 Jul; 30(3):515-538. PubMed ID: 38726504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced ethanol catabolism in orphan nuclear receptor SHP-null mice.
    Park JE; Lee M; Mifflin R; Lee YK
    Am J Physiol Gastrointest Liver Physiol; 2016 May; 310(10):G799-807. PubMed ID: 26968209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD).
    Lopez-Pascual A; Russo-Cabrera JS; Ardaiz N; Palmer T; Graham AR; Uriarte I; Gomar C; Ruiz-Guillamon D; Latasa MU; Arechederra M; Fontanellas A; Monte MJ; Marin JJG; Berasain C; Del Rio CL; Fernandez-Barrena MG; Martini PGV; Schultz JR; Berraondo P; Avila MA
    Clin Sci (Lond); 2024 Oct; 138(20):1265-1284. PubMed ID: 39301694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10.
    Yang Y; Lu J; Liu Y; Zhang N; Luo Y; Ma M; Dong Z; Zhang S; Zheng MH; Ruan CC; Wan X; Hu C; Lu Y; Ma X; Zhou B
    Mol Metab; 2024 Nov; 89():102030. PubMed ID: 39293565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver.
    Iacobini C; Menini S; Ricci C; Blasetti Fantauzzi C; Scipioni A; Salvi L; Cordone S; Delucchi F; Serino M; Federici M; Pricci F; Pugliese G
    J Hepatol; 2011 May; 54(5):975-83. PubMed ID: 21145823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).
    Sharma RS; Harrison DJ; Kisielewski D; Cassidy DM; McNeilly AD; Gallagher JR; Walsh SV; Honda T; McCrimmon RJ; Dinkova-Kostova AT; Ashford MLJ; Dillon JF; Hayes JD
    Cell Mol Gastroenterol Hepatol; 2018 Mar; 5(3):367-398. PubMed ID: 29552625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of STK39 weakens the MASLD/MASH process by protecting the intestinal barrier.
    Xu Q; Liu F; Wu Z; Chen M; Zhou Y; Shi Y
    Biosci Trends; 2024 Jul; 18(3):289-302. PubMed ID: 38925962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.